Mar 1, 2024 · Menactra is for use in children and adults between the ages of 9 months and 55 years old. Meningococcal disease is a bacterial infection that can infect the spinal cord and brain and cause meningitis, which can be fatal or lead to permanent and disabling medical problems.

Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. To revise the...

Jan 6, 2025 · Menactra ®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age.

Menactra® is indicated for active immunization for the prevention of invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135 in persons 9 months through 55 years of age.

Indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals. 0.5 mL/dose IM. No prevention...

Find patient medical information for Menactra (PF) intramuscular on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Dec 25, 2024 · Meningococcal conjugate vaccine is used to prevent infection caused by serogroups A, C, W, and Y. This vaccine helps your body develop immunity to meningitis, but will not treat an active infection you already have. The Menactra brand of this vaccine is for use in children and adults between the ages of 9 months and 55 years old.

Nov 15, 2006 · Tetravalent meningococcal polysaccharide-protein conjugate vaccine (MCV4; Menactra) has joined the tetravalent meningococcal polysaccharide vaccine (MPSV4; Menomune) as the second vaccine labeled...

This vaccine is used to help prevent certain serious, sometimes fatal, bacterial infections (meningitis, meningococcemia). This infection may cause severe problems (hearing loss, brain/nerve problems, paralysis, blindness, seizures, loss of limbs) even with antibiotic treatment.

Menactra is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals...